The effect of pentoxifylline and its metabolite-1 on inflammation and fibrosis in the TNBS model of colitis

European Journal of Pharmacology

Volumn 662, Issue 1-3, 2011, Pages 47-54

  Peterson, Theresa C ^a   Peterson, Marc R ^a   Raoul, Jennifer M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Fibrosis; Interleukin 18; Pentoxifylline; Trinitrobenzenesulfonic acid

Indexed keywords

COLLAGEN TYPE 1; INTERLEUKIN 18; LISOFYLLINE; MALACHITE GREEN; MYELOPEROXIDASE; PENTOXIFYLLINE; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLITIS; COLON INJURY; CONTROLLED STUDY; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVITY; EXPERIMENTAL MODEL; FEMALE; INTESTINAL FIBROSIS; LOW DRUG DOSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RAT; STRUCTURE ANALYSIS; THICKNESS; WESTERN BLOTTING;

ANIMALS; COLITIS; COLLAGEN TYPE I; COLON; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; INFLAMMATION; INTERLEUKIN-18; INTESTINES; ORGAN SIZE; PENTOXIFYLLINE; PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; TIME FACTORS; TRINITROBENZENESULFONIC ACID;

EID: 79957583692     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.04.030     Document Type: Article

References (61)

1. Appleyard, C.B., McCafferty, D.M., Tigley, A.W., Swain, M.G., Wallace, J.L., 1996. Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am. J. Physiol. 270, G42-G48.
2. Aricha, R., Feferman, T., Souroujon, M.C., Fuchs, S., 2006. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. FASEB J. 20, 374-376. (Pubitemid 46671176)
3. Bradley, P.P., Priebat, D.A., Christensen, R.D., Rothstein, G., 1982. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 78, 206-209.
4. Brooks, M.J., Green, J.R., 2004. Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Drugs 64, 1069-1089. (Pubitemid 38736895)
5. Bursten, S., Weeks, R., West, J., Le, T., Wilson, T., Porubek, D., Bianco, J.A., Singer, J.W., Rice, G.C., 1994. Potential role for phosphatidic acid in mediating the inflammatory responses to TNF-α and IL-1β. Circ. Shock 44, 14-29.
6. Carvalho, A.T., Souzoa, H., Carneiro, A.J., Castel-Branco, M., Madi, K., Schanaider, A., Silv, F., Pereira, Junior F.A., aPereira, M.G., Tortori, C., Dines, I., Carvalho, J., Rocha, E., Elia, C., 2007. Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production. World J. Gastroenterol. 13, 2166-2173.
7. Che, D., Huang, X., 1999. Chronic obstructive pulmonary disease and pulmonary structural remodeling. Zhonghua Jie He He Hu Xi Za Zhi 22, 472-474.
8. Coon, M.E., Diegel, M., Leshinsky, N., Klaus, S.J., 1999. Selective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling. J. Immunol. 163, 6567-6574.
9. Cotran, R.S., Kumar, V., Collins, T., 1999. The gastrointestinal tract, Robbins Pathologic Basis of Disease, 6th ed. WB Saunders Co, Philadelphia, PA.
10. D'Haens, G., Swijsen, C., Noman, M., Lemmens, L., Ceuppens, J., Agbahiwe, H., Geboes, K., Rutgeerts, P., 2001. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am. J. Gastroenterol. 96, 2564-2568.
11. Du, X., Weng, H., Cai, W., 2001. Histological changes in 20 hepatic fibrosis patients with chronic hepatitis B after recombinant human interferon-gamma treatment. Zhonghua Gan Zang Bing Za Zhi 9, 273-275.
12. Dutra, R., Cola, M., Leite, D., Bento, A., Claudino, R., Nascimento, A., Leal, P., Calixto, J. 2011. Inhibitor of PI3Kγ ameliorates TNBS-induced colitis in mice by affecting the functional activity of CD4(+) CD25(+) FoxP3(+) regulatory T cells. Br J Pharmacol. doi: 10.1111/j.1476-5381.2011.01226.x. [Epub ahead of print]
13. Ejeil, A.L., Gaultier, F., Igondjo-Tchen, S., Senni, K., Pellat, B., Godeau, G., Gogly, B., 2003. Are cytokines linked to collagen breakdown during periodontal disease progression? J. Periodontol. 74, 196-201. (Pubitemid 36322274)
14. Farmer, R.G., Whelan, G., Fazio, V.W., 1985. Long-term follow up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 88, 1818-1825.
15. Feagan, B.G., 2003. Maintenance therapy for inflammatory bowel disease. Am. J. Gastroenterol. 98, S6-S17.
16. Fiocci, C., 1998. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115, 182-205.
17. Fix, C., Bingham, K., Carver, W., 2011. Effects of interleukin-18 on cardiac fibroblast function and gene expression. Cytokine 53, 19-28.
18. Haas, S.L., Abbatista, M., Brade, J., Singer, M.V., Bocker, U., 2009. Interleulin-18 serum levels in inflammatory bowel disease; correlation with disease activity and inflammatory markers. Swiss Med Wkly 139, 140-145.
19. Haber, P.S., Keough, G.W., Apte, M.V., Moran, C.S., Stewart, N.L., Crawford, D.H., Pirola, R.C., McCaughan, G.W., Ramm, G.A., Wilson, J.S., 1999. Activation of pancreatic stellate cells in human and experimental pancreatic fibrosis. Am. J. Pathol. 155, 1087-1095.
20. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F., Rachmilewitz, D., Wolf, D.C., Olson, A., Bao, W., Rutgeerts, P., ACCENT I Study Group, 2002. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomised trial. Lancet 359, 1541-1549. (Pubitemid 34621118)
21. Harper, P.H., Fazio, V.W., Lavery, I.C., Jagelman, D.G., Weakley, F.L., Farmer, R.G., Easley, K.A., 1987. The long-term outcome in Crohn's disease. Dis. Colon Rectum 30, 174-179. (Pubitemid 17030587)
22. Isbrucker, R.A., Peterson, T.C., 1998. Platelet-derived growth factor and pentoxifylline modulation of collagen synthesis in myofibroblasts. Toxicol. Appl. Pharmacol. 149, 120-126.
23. Isik, F., Tunali, Akbay.T., Yarat, A., Genc, Z., Pisiriciler, R., Caliskan-Ak, E., Cetinel, S., Altintas, A., Sener, G., 2011. Protective effects of black cumin (Nigella sativa) oil on TNBS-induced experimental colitis in rats. Dig. Dis. Sci. 56, 721-730.
24. Jimenez, J.L., Punzon, C., Navarro, J., Muñoz-Fernández, M.A., Fresno, M., 2001. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T-lymphocytes by inhibiting nuclear factor-κB and nuclear factor of activated T cells activation. J. Pharmacol. Exp. Ther. 229, 753-759.
25. Khan, F., Peltekian, K.M., Peterson, T.C., 2008. Effect of interferon-alpha, ribavirin, pentoxifylline, and interleukin-18 antibody on hepatitis C sera-stimulated hepatic stellate cell proliferation. J. Interferon Cytokine Res. 28, 643-651.
26. Kimura, R., Hu, H., Stein-Steillien, J., 1992. Delayed-type hypersensitivity responses regulate collagen deposition in the lung. Immunology 77, 550-555. (Pubitemid 23000476)
27. Krawisz, J.E., Sharon, W.F., 1984. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology 87, 1344-1350.
28. Last, J.A., Ward, R., Temple, L., Pinkerton, K.E., Kenyon, N.J., 2004. Olvalbumin-induced airway inflammation and fibrosis in mice also exposed to ultrafine particles. Inhal. Toxicol. 16, 93-102.
29. Lawrance, I.C., Maxwell, L., Doe, W., 2001. Altered response of intestinal mucosal fibroblasts to profibrogenic cytokines in inflammatory bowel disease. Inflamm. Bowel Dis. 7, 226-236.
30. Lin, S.L., Chen, Y.M., Chien, C.T., Chiang, W.C., Tsai, C.C., Tsai, T.J., 2002. Pentoxifylline attenuated the renal disease progression in rats with remnant kidney. J. Am. Soc. Nephrol. 13, 2916-2929.
31. Lopez de Leon, A., Rojkind, M., 1985. A simple micromethod of for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J. Histochem. Cytochem. 33, 737-743.
32. Miroliaee, A.E., Esmaily, H., Vaziri-Bami, A., Baeeri, M., Shahverdi, A.R., Abdollahi, M., 2011. Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture. Toxicol. Mech. Methods 21, 200-208.
33. Morris, G.P., Beck, P.L., Herridge, M.S., Depew, W.T., Szewezuk, M.R., Wallace, J.L., 1989. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96, 795-803. (Pubitemid 19057602)
34. Mourelle, M., Salas, A., Vilaseca, J., Guarner, F., Malagelada, J.R., 1995. Induction of chronic cholangitis in the rat by trinitrobenzenesulfonic acid. J. Hepatol. 22, 219-225.
35. Murphy, G.J., Nicholson, M.L., 2003. Rapamycin has no effect on fibrosis-associated gene expression or extracellular matrix accumulation when administered to animals with established or early allograft vasculopathy. J. Thorac. Cardiovasc. Surg. 126, 2058-2064.
36. Murthy, S., Cooper, H.S., Yoshitake, H., Meyer, C., Meyer, C.J., Murthy, N.S., 1999. Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate sodium-induced mouse colitis. Aliment. Pharmacol. Ther. 13, 251-260.
37. Peterson, T.C., 1993. Pentoxifylline prevents fibrosis in an animal model and inhibits platelet-derived growth factor-driven proliferation of fibroblasts. Hepatology 17, 486-493. (Pubitemid 23072825)
38. Peterson, T.C., Davey, K., 1997. Effect of acute pentoxifylline treatment in an experimental model of colitis. Aliment. Pharmacol. Ther. 11, 575-580.
39. Peterson, T.C., Isbrucker, R., Hooper, M.L., 1994. In vitro effect of platelet-derived growth factor on fibroproliferation and effect of cytokine antagonists. Immunopharmacol 28, 259-270.
40. Peterson, T.C., Peterson, M.R., Wornell, P.A., Blanchard, M.G., Gonzalez, F.J., 2004. Role of CYP1A2 and CYP2E1 in the pentoxifylline ciprofloxacin drug interaction. Biochem. Pharmacol. 68, 395-402.
41. Pinzani, M., 1995. Novel insights into the biology and physiology of the Ito cell. Pharmacol. Ther. 66, 387-412.
42. Preaux, A.M., Mallat, A., Rosenbaum, J., Zafrani, E.S., Mauvier, P., 1997. Pentoxifylline inhibits growth and collagen synthesis of cultured human myofibroblasts-like cells. Hepatology 26, 315-322. (Pubitemid 27328307)
43. Pucilowska, J.B., Williams, K.L., Lund, P.K., 2000. Fibrogenesis IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G653-G659.
44. Puig-Divi, V., Molero, X., Salas, A., Guarner, F., Guarner, L., Malagelada, J.R., 1996. Induction of chronic pancreatic disease by trinitrobenzene sulfonic acid infusion into rat pancreatic ducts. Pancreas 13, 417-424. (Pubitemid 26357304)
45. Raoul, J.M., Peterson, M.R., Peterson, T.C., 2007. A novel drug interaction between the quinolone antibiotic ciprofloxacin and a chiral metabolite of pentoxifylline. Biochem. Pharmacol. 74, 639-646.
46. Reimund, J.M., Dumont, S., Muller, C.D., Kenney, J.S., Kedinger, M., Baumann, R., Poindron, P., Duclos, B., 1997. In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. Gut 40, 475-480.
47. Rogler, G., Andus, T., 1998. Cytokines in inflammatory bowel disease. World J. Surg. 22, 382-389.
48. Stein, R.B., Hanauer, S.B., 2000. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 23, 429-448.
49. Rojas-Cartagena, C., Flores, I., Appleyard, C.B., 2005. Role of tumor necrosis factor receptors in an animal model of acute colitis. Cytokine 32, 85-93. (Pubitemid 41563038)
50. Samardzic, T., Jankovic, V., Stosic-Grujicic, S., Popadic, D., Trajkovic, V., 2001. Pentoxifylline inhibits the synthesis and IFN-gamma-inducing activity of IL-18. Clin. Exp. Immunol. 124, 274-281.
51. Sturm, A., Zeeh, J., Sudermann, T., Rath, H., Gerken, G., Dignass, A., 2002. Lisofylline and lysophospholipids ameliorate experimental colitis in rats. Digestion 66, 23-29. (Pubitemid 36151287)
52. Valente, E.G.A., Vernet, D., Ferrini, M.G., Qian, A., Rajfer, J., Gonzalez-Cadavid, N.F., 2003. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 9, 229-244. (Pubitemid 38294362)
53. Verma, M., Peterson, M.R., Peterson, T.C., 2007. Effect of fetuin, a TGF beta antagonist and pentoxifylline, a cytokine antagonist on hepatic stellate cell function and fibrotic parameters in fibrosis. Eur. J. Pharmacol. 572, 220-227.
54. Videla, S., Garcia-Lafuente, A., Antolin, M., Vilaseca, J., Guarner, F., Crespo, E., Gonzalez, G., Salas, A., Malagelada, J.R., 1998. Antitumor necrosis factor therapy in rat chronic granulomatous colitis: critical dose-timing effects on outcome. J. Pharmacol. Exp. Ther. 287, 854-859.
55. Vukanić, Z.S., Colić, M., Dimitrijević, M., 2007. Effect of pentoxifylline on differentiation and maturation of human monocyte-derived dendritic cells in vitro. Int. Immunopharmacol. 7, 167-174.
56. Wallace, J.L., 1987. Glucocorticoid-induced gastric mucosal damage: inhibition of leukotriene, but not prostaglandin biosyntheisis. Prostaglandins 34, 311-323. (Pubitemid 18044353)
57. Wallace, J.L., MacNaughton, W.K., Morris, G.P., Beck, P.L., 1989. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 96, 29-36. (Pubitemid 19046263)
58. Ward, A., Clissold, S.P., 1987. Pentoxifylline, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 34, 50-97. (Pubitemid 17092322)
59. Yin, B., Hu, X., Wang, J., Liang, H., Li, X., Niu, N., Li, B., Jiang, X., Li, Z., 2011. Blocking TNF-α by combination of TNF-α- and TNFR-binding cyclic peptide ameliorates the severity of TNBS-induced colitis in rats. Eur. J. Pharmacol. 656 (1-3), 119-124.
60. Zar, J.H., 1974. Biostatistical Methods. Prentice-Hall, Englewood Cliffs, N.J.
61. Zhang-Hoover, J., Sutton, A., van Rooijen, N., Stein-Streilein, J., 2000. A critical role for alveolar macrophages in elicitation of pulmonary immune fibrosis. Immunology 101, 501-511. (Pubitemid 32001465)